An observational study in Hypoparathyroidism, sponsored by Ascendis Pharma A/S. Recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Ascendis Pharma A/S · Observational
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
This study's planned enrollment of 50 is below the median of 147 across 48 observational studies indexed under Hypoparathyroidism.
Browse Hypoparathyroidism studies →Ascendis Pharma A/S is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with exposure to at least one dose of YORVIPATH at any time within 15 days prior to conception or during pregnancy. Prospective and retrospective pregnancies may be reported.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women exposed to palopegteriparatide during pregnancy
Drug: Palopegteriparatide
Palopegteriparatide prescribed as per normal clinical practice
The number of fetuses as reported by HCP
Time frame: 21 months
Pregnancy outcomes
* Live birth (preterm delivery, full-term delivery) * Spontaneous abortion * Pregnancy termination * Fetal death/stillbirth * Molar or ectopic pregnancy
Time frame: 21 months
Number of congenital malformations identified in the developing fetus, neonate, or infant
Time frame: 21 months
Descriptive statistics of adverse events (AEs), including serious adverse events (SAEs)
Time frame: 21 months
Number of hospitalizations including reasons for hospitalization
Time frame: 21 months
Descriptive statistics of growth and development milestones as described by the Centers for Disease Control and Prevention (CDC 2021) or other accepted standard assessment
Time frame: 21 months
Number of signs of hypocalcemia or hypercalcemia
Time frame: 21 months
Descriptive statistics of infant developmental deficiency (CDC 2021)
Time frame: 21 months
Descriptive statistics of postnatal growth deficiency or failure to thrive (FTT)
Time frame: 21 months
Descriptive statistics of neonatal and infant mortality
Time frame: 21 months
Maternal complications of pregnancy
Including but not limited to * Premature rupture of membranes (PROM) * Preterm PROM (PPROM) * Pre-eclampsia * Gestational hypertension * Eclampsia * Proteinuria * Gestational diabetes * Intrauterine growth restriction (IUGR) * Polyhydramnios * Preterm delivery * Measures of fetal growth deficiency (e.g., small for gestational age)
Time frame: 21 months
Other maternal events of interest
Number of * AEs, including SAEs * Events specific to hypoparathyroidism (e.g., hypercalcemia, hypocalcemia). Serum calcium concentrations at each trimester (if available) and at birth
Time frame: 21 months
Started Feb 2026 (actual). Primary completion is estimated for Jan 2036, 119 months after the start.
Of 25 observational studies under Hypoparathyroidism, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 122. This study's planned 119 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ascendis Pharma A/S